MedVi vs BreezeMeds: Semaglutide, Pricing, and Service Compared
MedVi vs BreezeMeds answers whether you want a low promotional entry into compounded semaglutide with 24/7 clinician support or a platform that lists multiple injectable and oral GLP-1 options. Early verdict: MedVi emphasizes a $179 first-month compounded semaglutide promo and no clinic visits, while BreezeMeds highlights a broader menu including semaglutide from $199 and tirzepatide from $299, so choose based on whether price-first-month or broader medication options matter most.
See MedVi $179 first-month offer
What differs most: price, medication options, and clinical model
The two providers diverge on three to five clear points supported by the source material: starting price structure, medication breadth, telehealth process and support, compounded versus branded status, and clarity of fees. Below we compare each area directly using only supplied facts.
Starting price and promotional structure
MedVi reports a winter promotional price of $179 for the first month including fast, free shipping, but notes ongoing standalone months cost $299 and a three-month plan is $649 (about $216/month). BreezeMeds lists semaglutide injections starting at $199, tirzepatide injections from $299, and oral options from $399, with a separate $169 figure present but not tied to a specific product.
Medication variety: semaglutide only vs multiple GLP-1s
MedVi is presented as offering compounded semaglutide only. BreezeMeds displays multiple options: semaglutide injection, tirzepatide injection, and oral semaglutide and tirzepatide, with stated starting prices for each. If access to tirzepatide or oral formulations is important, BreezeMeds indicates those options are available while MedVi lists semaglutide only.
Telehealth process, clinician review, and support
MedVi highlights a simple online intake with no clinic visits and 24/7 support from certified medical professionals, and notes prescriptions require clinician review through an affiliated clinician network. BreezeMeds shows an online intake and clinician-reviewed treatment with discreet home delivery; source text emphasizes treatment availability only when a licensed clinician determines it is medically appropriate. Both require clinician review, but MedVi specifically advertises 24/7 certified medical support and no in-person visits.
Compounded medications and regulatory notes
MedVi explicitly states it provides clinically dosed compounded semaglutide and includes a regulatory note that compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality. BreezeMeds also indicates that compounding and medication-specific approval status must be confirmed and that branded and compounded products are not interchangeable. Both providers flag the need to confirm FDA status when compounded products are relevant.
Clarity of fees and enrollment commitments
MedVi’s pricing presentation includes a clear promotional first-month price and subsequent standalone and multi-month plan amounts, and notes medication is included in program costs and the first month has no contract. BreezeMeds shows multiple starting prices but includes ambiguity: a $169 figure is present without a clear product association and fees and billing commitments were not fully visible in captured evidence. The source suggests prospective users confirm total cost and renewal terms with BreezeMeds before enrollment.
| Criteria | MedVi | BreezeMeds |
|---|---|---|
| Starting price | Promotional first month $179; $299 standalone month; three-month plan $649 (~$216/mo) | Semaglutide injection from $199; tirzepatide injection from $299; oral from $399; unclear $169 figure |
| Medication options | Compounded semaglutide only | Semaglutide and tirzepatide, injectable and oral options displayed |
| Telehealth model | Simple online intake, no clinic visits, 24/7 certified medical support | Online intake with clinician review and discreet home delivery |
| Compounded regulatory status | Compounded semaglutide; not FDA-approved or reviewed | Compounding and approval status must be confirmed; branded and compounded not interchangeable |
| Fee clarity | Detailed promo and ongoing prices provided; medication included in program cost | Multiple starting prices shown; fees, billing, and commitment terms not fully visible |
Service strengths and limitations in practice
MedVi’s strengths are a low promotional entry point, a fully remote intake with no clinic visits, and 24/7 certified medical support. Its limitations include higher ongoing month-to-month pricing after the promotion and offering only compounded semaglutide. BreezeMeds’ strengths are a broader set of injectable and oral GLP-1 options and discreet home delivery; its limitations include less clear fee presentation and a noted need to confirm medication-specific approval status and state availability.
View BreezeMeds medication options
How eligibility and clinician review factor in
Both platforms require clinician review and determine treatment suitability during intake. MedVi states OpenLoop Health clinicians retain prescribing discretion and that some individuals may be screened out. BreezeMeds states treatment is available only when a licensed clinician determines it is medically appropriate. Neither provider’s captured evidence guarantees eligibility for any individual.
Check MedVi clinician review process
Conclusion: MedVi vs BreezeMeds — who should pick which
In summary, MedVi vs BreezeMeds comes down to whether you prioritize a lower first-month promotional price plus continuous remote support, or you need access to multiple GLP-1 medication types and formulations. Both require clinician review and flag compounded medication regulatory considerations.
Choose MedVi if you want a promotional first-month compounded semaglutide program starting at $179, a simple online intake with no clinic visits, and 24/7 certified medical support.
Choose BreezeMeds if you need a provider that displays multiple injectable and oral GLP-1 options including tirzepatide and you will confirm the exact product, state availability, and billing terms before enrolling.